It was supported with clinical evidence that blood cancers are especially responsive to HDAC inhibitors, and Vorinostat is one of the promising options for blood cancers with manageable drug‐related adverse events.[38] Moreover, Vorinostat was approved by US Food and Drug Administration (FDA) to treat advanced cutaneous T‐cell lymphoma (CTCL).[38] Similarly, there is a different proportion of Sorafenib‐sensitive cell lines between solid cancer and blood cancer (10/251, 3.98% vs 21/142, 14.79%; Fisher's exact test: p = 0.0003). The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.